CINCINNATI, June 16, 2011 /PRNewswire/ -- Kendle (Nasdaq:
KNDL), a leading, global full-service clinical research
organization, today announced several of its senior clinical
development experts will present on important industry issues at
the Drug Information Association (DIA) 47th Annual Meeting,
June 19-23, 2011, in Chicago. Kendle experts will address key
topics, including the benefits of hybrid monitoring; finding an
economic balance between cost and reimbursement; and strategic
development planning for clinical trials programs. Company
executives will be available throughout the conference at booth
#1343 for on-site meetings and to discuss why partnering with
Kendle is an important step toward clinical development project
success.
The 2011 DIA Annual Meeting bills itself as the "largest global,
multidisciplinary gathering of biopharmaceutical professionals
whose agenda is clear: to find immediate solutions to the most
pressing needs of our industry for today and tomorrow." With the
cost of drug development today estimated at well over $1 billion, the biopharmaceutical industry is
under immense and growing pressure to drive efficiencies into the
clinical development process and control costs. Partnering with
global CROs, such as Kendle, that offer strong geographic,
therapeutic and functional expertise across Phase I through IV is
an important part of the solution. Independent research by the
Tufts Center for the Study of Drug Development indicates clinical
trials conducted by CROs are completed an average of 30 percent
more quickly than those conducted in-house, resulting in an average
time savings of four to five months and translating to $120 million to $150 million in increased revenue
potential.
Kendle Speakers at DIA:
Tuesday, June 21, 10-11:30 a.m., Session 213, Room W181a
Symposium: Monitoring and Source Verification: New Approaches to
Quality
Title: Producing Quality Data for Clinical Trials: Is Full Onsite
Monitoring the Only Answer?
Lisa Gorman, CCRR
Director, Clinical Operations – Project Coordination Services
Wednesday, June 22,
1:30-3 p.m., Session 358, Room
W184d
Symposium: Using Real-world Data for Making Real-world
Decisions
Title: In-patient Cost and Reimbursement for Patients with
Progressive Malignant Thoracic
Neoplasm in Germany
Florian Eichmann, PhD, MSc
Director, Registries and Health Outcomes
Thursday, June 23, 9-10:30 a.m., Session 402, Room W474b
Workshop: Strategic Development Planning: Designing Fast and
Efficient Programs
William K. Sietsema, PhD
Vice President, Regulatory Consulting and Submissions
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is a leading global
clinical research organization providing the full range of early-
to late-stage clinical development services for the world's
biopharmaceutical industry. Our focus is on innovative solutions
that reduce cycle times for our customers and accelerate the
delivery of life-enhancing products to market for the benefit of
patients worldwide. As one of the world's largest global providers
of Phase I-IV services, we offer experience spanning more than 100
countries, along with industry-leading patient access and retention
capabilities and broad therapeutic expertise, to meet our
customers' clinical development challenges.
For more information, please visit www.kendle.com.
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements relating to the value of
partnering with Kendle. Words such as "anticipate," "believe,"
"plan," "estimate," "expect," "intend," "will," "should," "may,"
and other similar expressions are intended to identify
forward-looking statements. Such statements are based upon the
current beliefs and expectations of Kendle's management and involve
a number of significant risks and uncertainties, many of which are
difficult to predict and are generally beyond the control of
Kendle. Actual results may differ materially from the results
anticipated in these forward-looking statements. Additional factors
that could cause Kendle's results to differ materially from those
described in the forward-looking statements can be found in the
periodic reports filed with the Securities and Exchange Commission,
which are available at the Securities and Exchange Commission's
website (http://www.sec.gov) at no charge. Kendle assumes no
responsibility to update any forward-looking statements as a result
of new information or future developments except as expressly
required by law.
SOURCE Kendle International Inc.